Skip to main content
Premium Trial:

Request an Annual Quote

Roche Signs Epigenomics for Cancer Diagnostic, Prognostic Collaboration

NEW YORK, March 18 - Roche and Epigenomics announced today a three-year collaboration to develop molecular diagnostic and pharmacagenomic assays for cancer that use Epigenomics' DNA methylation technologies.

 

Under the agreement, Roche will pay Epigenomics, of Seattle, Euro 4 million ($4.25 million), as well as R&D funding, milestone payments, and royalties on sales of products, that could total up to Euro 100 Million ($106.3 million).

 

The products to be developed include diagnostic and prognostic tools for colon, breast, and prostate cancer, as well as pharmacagenomics tests to predict response to anti-cancer drugs, the companies said. Roche will use its PCR and microarray technology in the assays.

 

The methylation technologies involve measuring the differences in DNA methylation between diseased and healthy conditions. Methylation, the phenomenon wherein a methyl group is attached to the cytosine base on DNA, is a major mechanism of control for gene expression.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.